Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Appleton

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.
Brain : a Journal of Neurology|May 8, 2007
Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathiesHaiyan Zhou, Heinz Jungbluth, Caroline A Sewry, et al.
Epilepsy & Behavior : E&B|January 16, 2019
How can transition to adult care be best orchestrated for adolescents with epilepsy?Peter R Camfield, Danielle Andrade, Carole S Camfield, et al.
Brain : a Journal of Neurology|April 20, 2013
Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrumAmy McTague, Richard Appleton, Shivaram Avula, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|September 16, 2005
Nonconvulsive status epilepticus: Epilepsy Research Foundation workshop reportsMatthew Walker, Helen Cross, Shelagh Smith, et al.
Neurology|December 3, 2017
Clinical and molecular characterization of <i>KCNT1</i>-related severe early-onset epilepsyAmy McTague, Umesh Nair, Sony Malhotra, et al.
Lancet (London, England)|March 27, 2007
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialAnthony G Marson, Asya M Al-Kharusi, Muna Alwaidh, et al.
Lancet (London, England)|March 27, 2007
The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialAnthony G Marson, Asya M Al-Kharusi, Muna Alwaidh, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Lancet (London, England)|April 11, 2021
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trialAnthony Marson, Girvan Burnside, Richard Appleton, et al.
Health Technology Assessment (Winchester, England)|December 21, 2021
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTsAnthony G Marson, Girvan Burnside, Richard Appleton, et al.
Brain : a Journal of Neurology|May 8, 2007
Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathiesHaiyan Zhou, Heinz Jungbluth, Caroline A Sewry, et al.
Epilepsy & Behavior : E&B|January 16, 2019
How can transition to adult care be best orchestrated for adolescents with epilepsy?Peter R Camfield, Danielle Andrade, Carole S Camfield, et al.
Brain : a Journal of Neurology|April 20, 2013
Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrumAmy McTague, Richard Appleton, Shivaram Avula, et al.
Epileptic Disorders : International Epilepsy Journal with Videotape|September 16, 2005
Nonconvulsive status epilepticus: Epilepsy Research Foundation workshop reportsMatthew Walker, Helen Cross, Shelagh Smith, et al.
Neurology|December 3, 2017
Clinical and molecular characterization of <i>KCNT1</i>-related severe early-onset epilepsyAmy McTague, Umesh Nair, Sony Malhotra, et al.
Lancet (London, England)|March 27, 2007
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trialAnthony G Marson, Asya M Al-Kharusi, Muna Alwaidh, et al.
Lancet (London, England)|March 27, 2007
The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialAnthony G Marson, Asya M Al-Kharusi, Muna Alwaidh, et al.
Pageof 7